| Literature DB >> 28322288 |
Lujia Wang1, Chenchen Feng1, Minwei Zhou2, Zhongwen Zhou3, Guanxiong Ding1, Peng Gao1, Qiang Ding1, Zhong Wu1.
Abstract
Extramammary Paget's disease (EMPD) is a rare malignancy, and little was known about its prognostic factors and optimal treatment. In the current study, we aimed to discuss clinical and pathological features of scrotal EMPD and determine the prognostic factors for cancer-specific survival and local recurrence. A total of 206 patients with scrotal EMPD lesions surgically treated at our institute were studied. All clinical and pathological data were reviewed. Immunohistochemical staining of TP53 and Ki67 was examined as well. At the last follow-up, 175 patients (84.95%) were alive. Twelve patients (5.83%) had died of the disease due to distant metastases. Fifteen patients (7.28%) developed local recurrences of scrotal EMPD. Ki67 expression was significantly elevated in patients with wide horizontal invasion (P = 0.003). In univariate analysis, high invasion level, presence of nodule, presence of lymphovascular invasion, adnexa invasion, lymph node metastasis and high p53 expression were significant factors for poor cancer-specific survival. In multivariate analysis, high p53 expression was significantly correlated with poor cancer-specific survival. Wide horizontal invasion was independently correlated with local recurrence-free survival of scrotal EMPD. In conclusion, wide horizontal invasion is an independent risk factor for local recurrence-free survival in the patients with scrotal EMPD.Entities:
Mesh:
Year: 2017 PMID: 28322288 PMCID: PMC5359569 DOI: 10.1038/srep44933
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographics and clinical data.
| Parameter | n (%) | |
|---|---|---|
| Age (years) | 67.23 ± 8.970 | |
| Delay in diagnosis (years) | 3.42 ± 3.135 | |
| Recurrent disease | 23 (11.17%) | |
| Large tumor size (>25.0 cm2) | 86 (41.75%) | |
| Multiple lesions | 23 (11.17%) | |
| Invasion level | 183 (88.84%) | |
| Micro-invasion | 10 (4.85%) | |
| Deep invasion | 13 (6.31%) | |
| Nodule formation | 9 (4.37%) | |
| Ulceration | 10 (4.85%) | |
| Lymphovascular invasion | 8 (3.88%) | |
| Adnexa invasion | 27 (13.11%) | |
| Wide horizontal invasion | 52 (25.24%) | |
| Lymph node metastasis | 10 (4.85%) | |
| 206 | ||
aAll numerical variables were presented as mean ± standard deviation.
Figure 1Histopathology of scrotal EMPD. (A) Within the epidermis; (B) Invades the dermis; (C) Adnexa invasion. (H&E, capture at ×200).
Figure 2Immunohistochemistry of (A) p53 and (B) Ki67 in scrotal EMPD. (capture at ×200).
Ki67 and p53 expressions in relation to clinicopathological parameters (mean ± SD).
| Ki67(%)b | p53 | |||
|---|---|---|---|---|
| Positive expression (n,%)c | Expression scoreb,d | |||
| Delay in diagnosis (years) | <7 | 33.45 ± 20.18 | 116 (63.4%) | 1.04 ± 0.31 |
| ≥7 | 32.96 ± 21.46 | 15 (65.2%) | 1.18 ± 0.41 | |
| P | 0.915 | 0.864 | 0.162 | |
| Tumor size (cm2) | ≤25.0 | 34.98 ± 20.65 | 69 (57.5%) | 1.04 ± 0.26 |
| >25.0 | 31.33 ± 19.79 | 60 (69.8%) | 1.06 ± 0.39 | |
| P | 0.255 | 0.073 | 0.806 | |
| Multiple lesions | Absent | 34.01 ± 20.35 | 114 (62.3%) | 1.06 ± 0.35 |
| Present | 29.05 ± 19.85 | 16 (69.6%) | 1.00 ± 0.00 | |
| P | 0.296 | 0.496 | 0.056 | |
| Invasion level | 33.80 ± 20.41 | 117 (63.9%) | 1.04 ± 0.33 | |
| Micro-invasion | 23.56 ± 20.88 | 7 (70.0%) | 1.17 ± 0.41 | |
| Deep invasion | 35.91 ± 17.72 | 6 (46.2%) | 1.00 ± 0.00 | |
| P | 0.312 | 0.406 | 0.643 | |
| Nodule formation | Absent | 33.21 ± 19.95 | 126 (64.0%) | 1.05 ± 0.33 |
| Present | 37.14 ± 28.70 | 4 (44.4%) | 1.00 ± 0.00 | |
| P | 0.732 | 0.295 | 0.836 | |
| Ulceration | Absent | 32.99 ± 19.77 | 123 (62.8%) | 1.03 ± 0.27 |
| Present | 39.40 ± 27.87 | 7 (70.0%) | 1.33 ± 0.82 | |
| P | 0.334 | 0.643 | 0.028* | |
| Lymphovascular Invasion | Absent | 33.27 ± 20.28 | 129 (65.2%) | 1.05 ± 0.33 |
| Present | 35.50 ± 21.82 | 2 (25.0%) | 1.00 ± 0.00 | |
| P | 0.763 | 0.028* | 0.836 | |
| Adnexa invasion | Absent | 32.55 ± 20.16 | 111 (62.0%) | 1.04 ± 0.34 |
| Present | 37.59 ± 20.86 | 19 (70.4%) | 1.08 ± 0.29 | |
| P | 0.239 | 0.401 | 0.691 | |
| Wide horizontal | ≤2.0 | 32.07 ± 19.18 | 95 (61.7%) | 1.05 ± 0.37 |
| >2.0 | 44.49 ± 23.67 | 35 (67.3%) | 1.04 ± 1.92 | |
| P | 0.003** | 0.468 | 0.840 | |
| Lymph node metastasis | Absent | 33.77 ± 20.24 | 127 (64.8%) | 1.05 ± 0.33 |
| Present | 26.56 ± 21.20 | 3 (30.0%) | 1.00 ± 0.00 | |
| P | 0.301 | 0.040* | 0.884 | |
**Correlation is significant at the 0.01 level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed).
bThe student t test was applied to compare scores of ki67 and p53 between two groups. Analysis of variance (ANOVA) was applied for comparison of more than 2 groups.
cChi-square analysis was applied for comparison of p53-positive rate between different groups. Fisher exact tests were used if any expected value was less than 5.
dAll p53-negative patients were excluded.
Univariate analysis for cancer-specific survival.
| Parameter | Patients(n) | Died of disease(n) | Pe | |
|---|---|---|---|---|
| Age(years) | <70 | 184 | 11 | 0.530 |
| ≥70 | 22 | 1 | ||
| Delay in diagnosis(years) | <7 years | 183 | 10 | 0.651 |
| ≥7 years | 23 | 2 | ||
| Tumor size(cm2) | ≤25.0 | 120 | 8 | 0.482 |
| >25.0 | 86 | 4 | ||
| Multiple lesions | Absent | 183 | 12 | 0.169 |
| Present | 23 | 0 | ||
| Invasion level | 183 | 6 | <0.0001** | |
| Micro-invasion | 10 | 0 | ||
| Deep invasion | 13 | 6 | ||
| Nodule formation | Absent | 197 | 9 | <0.0001** |
| Present | 9 | 3 | ||
| Ulceration | Absent | 196 | 12 | 0.404 |
| Present | 10 | 0 | ||
| Lymphovascular invasion | Absent | 198 | 5 | <0.0001** |
| Present | 8 | 7 | ||
| Adnexa invasion | Absent | 178 | 8 | 0.017* |
| Present | 28 | 4 | ||
| Wide horizontal invasion | ≤2.0 cm | 154 | 10 | 0.584 |
| >2.0 cm | 52 | 2 | ||
| Recurrence disease | Absent | 183 | 10 | 0.651 |
| Present | 23 | 2 | ||
| Lymph node metastasis | Absent | 196 | 5 | <0.0001** |
| Present | 10 | 7 | ||
| Ki67 expression | <20% positive | 68 | 5 | 0.836 |
| ≥20% positive | 125 | 8 | ||
| p53 expression | Negative | 72 | 9 | 0.026* |
| Low expression | 115 | 1 | ||
| High expression | 8 | 1 | ||
**Correlation is significant at the 0.01 level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed).
eSurvival curves were compared using the Log-rank test.
Multivariate Cox regression analysis for cancer-specific survival.
| Variables | HR | 95%CI | Pf | |
|---|---|---|---|---|
| Age | (<70 years/≥70years) | 0.001 | 0.000–3.227E25 | 0.844 |
| Delay in diagnosis | (<7years/≥7years) | 0.000 | 0.000–1.182E55 | 0.900 |
| Recurrence disease | (Absent/Present) | 0.002 | 0.000–4.094E47 | 0.915 |
| Tumor size | (≤25 cm2/>25 cm2) | 1.196 | 0.054–26.693 | 0.910 |
| Multiple lesions | (Absent/Present) | 0.001 | 0.000–3.142E48 | 0.904 |
| Nodule formation | (Absent/Present) | 0.161 | 0.000–2.942E54 | 0.978 |
| Lymphovascular invasion | (Absent/Present) | 1.397E16 | 0.000–1.21E111 | 0.739 |
| Adnexa invasion | (Absent/Present) | 0.000 | 0.000–2.219E18 | 0.686 |
| Wide horizontal invasion | (≤2.0 cm/>2.0 cm) | 1.191 | 0.034–41.951 | 0.923 |
| Invasion level | — | — | 0.473 | |
| 1 | — | — | ||
| Micro-invasion | 0.001 | 0.000–2.945E65 | 0.933 | |
| Deep invasion | 10.742 | 0.237–486.051 | 0.222 | |
| Lymph node metastasis | (Absent/Present) | 0.000 | 0.000–2.463E75 | 0.807 |
| p53 expression | — | — | 0.045* | |
| Negative | 1 | — | — | |
| Low expression | 0.591 | 0.033–10.508 | 0.720 | |
| High expression | 152.280 | 1.665–1.393E4 | 0.029 | |
| Ki67 expression | (<20%/≥20% positive) | 0.554 | 0.021–14.446 | 0.723 |
**Correlation is significant at the 0.01 level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed).
fMultivariate Cox proportional regression was performed.
Multivariate Cox regression analysis for local recurrence-free survival.
| Variables | HR | 95%CI | Pf | |
|---|---|---|---|---|
| Age | (<70 years/≥70 years) | 0.256 | 0.028–2.347 | 0.228 |
| Delay in diagnosis | (<7 years/≥7 years) | 0.000 | 0.000–3.91E305 | 0.973 |
| Recurrence disease | (Absent/Present) | 0.594 | 0.066–5.340 | 0.642 |
| Tumor size | (≤25 cm2/>25 cm2) | 0.514 | 0.137–1.938 | 0.326 |
| Multiple lesions | (Absent/Present) | 0.924 | 0.219–3.903 | 0.914 |
| Nodule formation | (Absent/Present) | 0.000 | — | 0.986 |
| Lymphovascular invasion | (Absent/Present) | 0.001 | — | 0.997 |
| Adnexa invasion | (Absent/Present) | 0.000 | 0.000–8.91E289 | 0.971 |
| Wide horizontal invasion | (≤2.0 cm/>2.0 cm) | 5.142 | 1.262–20.956 | 0.022* |
| Invasion level | — | — | 0.999 | |
| 1 | — | — | ||
| Micro-invasion | 0.000 | — | 0.976 | |
| Deep invasion | 0.000 | — | 0.983 | |
| Lymph node metastasis | (Absent/Present) | 2.347 | — | 1.000 |
| p53 expression | — | — | 0.418 | |
| Negative | 1 | — | — | |
| Low expression | 4.248 | 0.496–36.370 | 0.187 | |
| High expression | 0.000 | — | 0.982 | |
| Ki67 expression | (<20%/≥20% positive) | 1.566 | 0.369–6.648 | 0.543 |
**Correlation is significant at the 0.01 level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed).
fMultivariate Cox proportional regression was performed.